Navigation Links
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
Date:3/29/2013

ompetition, and others stated in risk factors contained in our SEC filings.  We cannot assure that we have identified all risks or that others may emerge which we do not anticipate.  You should not place undue reliance on forward-looking statements.  Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

Galectin Therapeutics and its associated logo is a trademark of Galectin Therapeutics Inc.

 Condensed Consolidated Statements of OperationsThree Months
EndedDecember 31,Twelve MonthsEndedDecember 31,2012201120122011(in thousands, except per share data)

(unaudited)Operating expenses:  Research and development

$1,002

$862

$4,527

$3,552  General and administrative

1,380

2,510

5,372

6,857  Total operating expenses

2,382

3,372

9,899

10,409Total operating loss

(2,382)

(3,372)

(9,899)

(10,409)Other income and (expense):  Interest income

6

4

24

18  Change in fair value of warrant liabilities

-

-

-

(524)  Other income

-

-

200

-Total other income (expense)

6

4

224

(506)Net loss

$(2,376)

$(3,368)

$(9,675)

$(10,915)Preferred stock dividends and accretion costs

(332)

(350)

(1,206)

(1,798)Net loss applicable to common stock

$(2,708)

$(3,718)

$(10,881)

$(12,713)Basic and diluted net loss per share

$  (0.17)

$  (0.29)

$  (0.72)

$  (1.06)Shares used in computing basic and diluted net loss per share

15,966

12,846

15,131

11,986 Condensed Consolidated Balance She
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... This webinar will focus on EMA and ... in biosimilars. , Regulatory frameworks are evolving many countries ... the complex nature of biopharmaceuticals makes the demonstration of ... challenging. Based on the specific aspects of biosimilar drug ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Two champions ... continued their sponsorship of an annual competition for middle ... and access to, innovative STEM study. The competition presents ... TEAMS: Tests of Engineering Aptitude, Mathematics, and Sciences ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 2013 was ... Scottsdale’s Brain State Technologies®. They saw continued independent research ... Center who were awarded a $1 million grant from ... in “Brain and Behavior” a peer reviewed journal, Amy ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... Data to be Presented at the 7th International ... Symposium on Uveitis ... a leading,developer of antibody fragment therapeutics, today announced that the,company ... lead product candidate, ESBA105, in ophthalmic indications. In,April 2008, ESBATech ...
... DNA TESTING FOR $59.95, THE MOST AFFORDABLE PRICING AVAILABLE ... ... Sept. 8 Familybuilder today announces from,the DEMOfall 08 conference here ... http://www.familybuilder.com ) and the introduction of $59.95 DNA tests,the most ...
... NOCC Spokesperson, Eva La Rue, Lends Her Support as, ... Ovarian Cancer -, LOS ANGELES, Sept. 6 ... national haircare and styling partner,is hosting the first annual ... Cancer" at Dockweiler Beach in Playa del Ray, CA. ...
Cached Biology Technology:ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications 2Familybuilder Launches the Familybuilder Global Network at DEMOfall 08 2Familybuilder Launches the Familybuilder Global Network at DEMOfall 08 3National Ovarian Cancer Coalition and PureOlogy to Host First Annual 'NOCC and PureOlogy's Walk to Break the Silence on Ovarian Cancer' 2National Ovarian Cancer Coalition and PureOlogy to Host First Annual 'NOCC and PureOlogy's Walk to Break the Silence on Ovarian Cancer' 3
(Date:4/24/2014)... Ind. - Purdue and West Virginia University researchers are ... eagle, providing a bird,s-eye view of eagle features that ... Their study calls into question long-held assumptions about golden ... as sensitive to ultraviolet light as previously thought. The ... sharper sense of smell than researchers realized. , ...
(Date:4/24/2014)... Rochelle, NY, April 24, 2014D-ribose is a commercially ... supplement, and as a starting compound for synthesizing ... Escherichia coli to increase the bacteria,s ... toward achieving more efficient industrial-scale production of this ... Industrial Biotechnology , a peer-reviewed journal from ...
(Date:4/24/2014)... have invented a simple and cheap way of making ... into a high-resolution microscope. , Costing less than a ... medicine in developing countries and remote areas. , The ... from The Australian National University (ANU) Research School of ... Garvan Institute of Medical Research to find ways to ...
Breaking Biology News(10 mins):Genome yields insights into golden eagle vision, smell 2Droplet lens 2
... enables rice to survive complete submergence has beenidentified ... RiceResearch Institute in the Philippines and at the ... allows fordevelopment of new rice varieties that can ... and offering reliefto millions of poor rice farmers ...
... alien species have invaded, they usually find predictable patterns. ... in natural processes such as nutrient cycling, wildfire frequency ... , But simply observing such changes doesn't prove that ... researchers Emily Farrer and Deborah Goldberg, however, came up ...
... time in as many months, the IODP Arctic Coring Expedition ... In the Aug. 10 issue of Nature, an article by ... that the Arctic was extremely warm, unusually wet, and ice-free ... gases were released into the Earth's atmosphere ?a period calculated ...
Cached Biology News:New flood-tolerant rice offers relief for world's poorest farmers 2New flood-tolerant rice offers relief for world's poorest farmers 3Invasive species alter habitat to their benefit 2Invasive species alter habitat to their benefit 3Arctic coring expedition continues to yield new clues 2
Ezrin/Radixin/Moesin Antibody...
Anti-Mouse C-10, Biotin (Polyclonal) (rabbit IgG)...
... Rabbit polyclonal to ADAMTS16 ( Abpromise ... Antigen: Synthetic peptide ... human ADAMTS-16. Note: the amino acid ... Entrez GeneID: 170690 ...
Purified Mouse anti-Hu Actopaxin (pS8) Storage Temperature: Refrigerate(2 to 8C)...
Biology Products: